2CDA IN RELAPSING/REMITTING MULTIPLE SCLEROSIS

多发性硬化症(MS)是一种进行性神经系统疾病，可能有自身免疫基础。我们一直在测试Cladriine(2-CDA)作为治疗MS的安全性和有效性。其他目前的治疗方法并不令人满意，Beta干扰素和Copaxone对MS的复发有部分效果。我们已经完成了针对慢性进展性MS的治疗试验(子项目#220)，并已表明Cladriine，一种免疫抑制剂，可以将疾病的进展延迟两年或更长时间。一项双盲、安慰剂对照的克拉曲滨治疗复发缓解型多发性硬化症的临床试验刚刚完成。结果表明，克拉曲林治疗组MRI增强的脑部病变明显受到抑制，临床复发的严重程度和频率都显著降低。在本研究中使用的剂量下，皮下给药没有明显的毒性或副作用。

Multiple sclerosis (MS) is a progressive neurologic disorder that is likely to have an autoimmune basis. We have been testing the safety and efficacy of cladribine (2-CdA) as a treatment for MS. Other current treatments are unsatisfactory, with Beta Interferon and Copaxone having a partial effect on relapses in MS. We have completed treatment trials in chronic progressive MS (subproject #220) and have shown that cladribine, an immunosuppressive agent, retards the progression of the disease for two years or longer. A double-blind, placebo-controlled clinical trial of cladribine in relapsing-remitting MS has just been completed. The results indicate marked suppression of MRI-enhancing brain lesions in the cladribine treated group and significant reduction in both severity and frequency of clinical relapses. There was no significant toxicity or side effects of subcutaneously administered cladribine at the doses used in this study.